Preventing recurrent ischemic stroke: A 3-step plan

To prevent recurrent stroke, address the patient’s risk factors, clear stenosis, and thin the blood.

Practice recommendations

■ Once a stroke patient has stabilized, if there is no contraindication, consider starting an antihypertensive agent regardless of the baseline blood pressure.

■ For symptomatic patients with high-grade carotid stenosis (70% to 99%), plan a course of medical management plus carotid endarterectomy (CEA). With moderate carotid stenosis (50% to 69%), CEA offers only moderate stroke risk reduction.

■ When aspirin is the antiplatelet drug of choice, it is reasonable to use daily doses between 50 mg and 325 mg.

For patients with atherosclerotic ischemic infarction, 3 steps are needed to achieve the goal of preventing recurrent stroke: address risk factors, clear blocked arteries, and thin the blood.

Step 1: Address risk factors
Risk factors that are non-modifiable put patients at highest risk for recurrent stroke and dictate more aggressive management measures.

Advanced age is the most serious non-modifiable risk factor for stroke. Risk of stroke in those older than 65 years is 16 to 25 times higher than the risk for younger people.

Sex, family history, race, ethnicity, and geographic location also show a positive correlation with stroke incidence. Men are 1.25 times more likely to suffer stroke than women, although women account for 60% of stroke fatalities. The “stroke belt,” a cluster of 11 states in the southeastern United States, has considerably higher stroke mortality than the country as a whole. African Americans are at greater risk for primary ischemic stroke and stroke mortality than are whites.

Table 1 lists modifiable risk factors. Studies show that even after a stroke, these factors are often not aggressively treated, with most patients falling outside guideline recommendations for treatment of at least 1 risk factor. In risk management, the greatest benefit is in controlling hypertension.

Hypertension

Up to 50% of all strokes are attributable to hypertension, making this the most commonly encountered modifiable risk factor. Risk of stroke rises proportionately with increasing blood pressure. Systolic levels of 160 mm Hg or higher, or diastolic levels of 95 mm Hg or higher, carry a relative risk of approximately 4.

Even small reductions in blood pressure decrease the risk of stroke substantially.

The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recently...
released its JNC 7 Report,5 which says that increased risk for cardiovascular disease begins at systolic blood pressure of 115 mm Hg and diastolic blood pressure of 75 mg Hg.

The current recommendation for blood pressure control is <140/90 mm Hg, with tighter control (130/85 mm Hg) being prescribed for patients with diabetes.6 The JNC 7 report established a new classification: prehypertension (120/80 mm Hg to 130/89).7 For secondary stroke prevention, studies are under way to investigate the safety and efficacy of more aggressive medical management to target a systolic blood pressure target of 120 to 130 mm Hg.

Clinical trials with antihypertensive agents. Recent trials using various antihypertensive therapies have yielded apparently contradictory data. The only prospective randomized trial of antihypertensive agents focusing on secondary stroke prevention was the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). It enrolled 6105 patients with a history of stroke or transient ischemic attack (TIA) within 5 years of randomization. Patients were randomized to receive placebo or perindopril with or without indapamide (added at the treating doctor’s discretion) and were followed for 4 years.9

Patients in the treatment arm had a mean blood pressure reduction of 9/4 mm Hg. Relative risk reduction for stroke in the treatment arm was 28%. Stroke rate decreased by 43% (blood pressure reduction 12/5 mm Hg) for patients prescribed perindopril plus indapamide, while monotherapy with perindopril did not significantly reduce stroke rate. Benefit was found for patients not considered hypertensive at entry; the number of non-hypertensive patients needed to treat to prevent 1 major vascular event was 22.10

The Heart Outcomes Prevention Evaluation (HOPE) trial studied both primary and secondary stroke prevention, randomizing 9297 patients age 55 or over with high risk for vascular disease (coronary artery disease, stroke, peripheral vascular disease, or diabetes plus at least 1 other cardiovascular risk factor).11 Patients were treated with ramipril or placebo and followed for 5 years. The ramipril arm had a mean blood pressure reduction of 3/2 mm Hg, and exhibited a statistically significant 31% relative risk reduction in stroke. The risk reduction appears to be out of proportion to the blood pressure reduction, suggesting additional benefit from the angiotensin-converting enzyme inhibitor independent of its antihypertensive effect.

In the Losartan Intervention for Endpoint Reduction (LIFE) trial, addressing primary prevention, 9193 hypertensive patients were randomized to receive losartan or atenolol and were followed for a mean of 4.8 years.12 In the losartan arm, there was a 13% reduction in the combined endpoint of stroke, myocardial infarction (MI), and vascular death, with a 25% reduction in the rate of stroke despite a similar reduction in blood pressure in each arm.

In the largest of the trials, the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial

### Table 1

<table>
<thead>
<tr>
<th>FACTOR</th>
<th>PREVALENCE (%)</th>
<th>RELATIVE RISK</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertension</td>
<td>25–40</td>
<td>3–5</td>
</tr>
<tr>
<td>Elevated total cholesterol level (&gt;240 mg/dL [6.21 mmol/L])</td>
<td>6–40</td>
<td>1.8–2.6</td>
</tr>
<tr>
<td>Physical inactivity</td>
<td>25–50</td>
<td>2.0–3.5</td>
</tr>
<tr>
<td>Smoking</td>
<td>25</td>
<td>1.5</td>
</tr>
<tr>
<td>Diabetes</td>
<td>4–20</td>
<td>1.8–3.0</td>
</tr>
<tr>
<td>Obesity</td>
<td>18</td>
<td>1.8–2.4</td>
</tr>
<tr>
<td>Asymptomatic carotid stenosis (&gt;50%)</td>
<td>2–8</td>
<td>2</td>
</tr>
<tr>
<td>Alcohol consumption (&gt;5 drinks/d)</td>
<td>2–5</td>
<td>1.6</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>1</td>
<td>5 (nonvalvular) 17 (valvular)</td>
</tr>
</tbody>
</table>


In managing risk for stroke, the greatest benefit is in controlling hypertension.
The risks and costs of stroke

Stroke is the leading cause of adult disability, the second leading cause of dementia, and the third leading cause of death in the United States. Stroke survivors are at significantly increased risk for subsequent stroke, with more than 75% of secondary vascular events being stroke. Therefore, prevention of secondary stroke saves lives, prevents disability, and is a prudent allocation of medical resources. Direct costs attributable to stroke in the United States are estimated at $28.3 billion a year, with total costs greater than $50 billion.

Applying the evidence. Although no class of antihypertensive therapy is clearly superior to others for primary or secondary stroke prevention, it is clear that lowering blood pressure is effective.

Since most hypertensive stroke patients will require at least 2 agents to control blood pressure, using a thiazide diuretic or an agent to inhibit the renin-angiotensin system or both appears to be reasonable.

Once a stroke patient has stabilized, if there is no contraindication, consider starting an antihypertensive agent regardless of the baseline blood pressure.

Hypercholesterolemia

In general, higher levels of low-density lipoprotein (LDL) cholesterol increase the risk of vascular disease. Multiple high-quality prospective randomized trials have demonstrated improved vascular outcomes for patients with coronary artery disease. However, the direct link to secondary prevention after stroke is somewhat tenuous.

Clinical trials with statin therapy. Several trials have reported a benefit with statin therapy for primary stroke prevention. The Scandinavian Simvastatin Survival Study (4S) was the first to demonstrate that lowering cholesterol with a statin drug can reduce the risk of stroke by 30% compared with placebo in patients with hypercholesterolemia at high risk for vascular disease.

The Cholesterol And Recurrent Events (CARE) trial confirmed the benefit of statin therapy in reducing the rate of stroke in a population at high vascular risk. In the CARE trial, pravastatin reduced the rate of stroke by 31% compared with placebo.

The Medical Research Council Heart Protection Study (HPS) randomized 20,536 high-risk patients to receive 40 mg simvastatin daily or placebo. Researchers found a statistically significant 25% risk reduction in prespecified endpoint stroke with an even more impressive reduction of 30% in ischemic stroke. However, in the non-prespecified analysis of patients entering the trial with ischemic stroke or TIA, no benefit of statin therapy was found for secondary stroke prevention.

Applying available recommendations. Trials are under way to prospectively test the benefit of statin therapy for secondary stroke prevention. Until the results of those trials are available, guidelines are available to help with decision making. The NCEP III guidelines recommend a target LDL cholesterol level below 100 mg/dL for patients with symptomatic atherosclerotic disease.

Cardiac risk factors

Atrial fibrillation (AF), valvular disease, coronary artery disease, and recent large MI increase the risk for stroke. Of these, AF shows the strongest association. AF increases with age and is found in 5.9% of patients older than 65 years. It is present in more than one third of stroke patients older than 75 and is the most common cause of ischemic stroke in this age group. Although much less common than nonvalvular AF, valvular AF poses an even greater risk.
Applying the evidence. Prescribe warfarin for stroke patients with AF (see Anticoagulation, below). While there is a paucity of data on prevention in other causes of cardioembolic stroke, most patients with cardioembolic stroke may benefit from chronic anticoagulation.

Lifestyle risk factors

Cigarette smoking. Early studies on the association between cigarette smoking and stroke reported variable results. The Framingham Study, in a multivariate analysis, found that when hypertension and age are taken into account, smoking is a significant risk factor.27 In a prospective study of 7735 men, Wannamethee and colleagues found benefit to stopping smoking, with light smokers dropping to the level of nonsmokers and heavy smokers dropping to about a twofold risk of nonsmokers in 5 years.28 The benefit was greatest for hypertensive patients.

With the data now available, it is clear that cigarette smoking is a modifiable risk factor for ischemic infarction. Patients at risk for stroke should be given assistance in smoking cessation.

Alcohol use and abuse. The relationship between alcohol consumption and stroke risk is complex; risk with heavy use differs from that with light use. There may be racial differences in regard to alcohol risk and stroke.

Palomaki and colleagues found a protective effect of light alcohol use, with ≤50 g/wk reducing the risk of ischemic stroke.29 Data from the Framingham Study failed to show an association between alcohol consumption and ischemic stroke although there was a suggestion of reduced risk with wine.30 While the data are not completely clear, it is reasonable to recommend avoiding heavy alcohol consumption as a measure of stroke risk reduction.

Physical activity. Regular exercise has been shown to reduce the risk of cardiovascular disease by decreasing blood pressure, reducing obesity, and improving glucose homeostasis, all of which should help reduce stroke risk.
Studies looking for an association between exercise and reduced stroke risk have produced mixed results. An evidence-based recommendation cannot be made. However, in view of the low cost and low risk of the intervention, instituting a program of progressive physical activity as part of a risk reduction program after stroke is a reasonable recommendation.

The American Heart Association’s Guidelines for Primary Prevention of Cardiovascular Disease and Stroke from 2002 suggest there is a benefit from vigorous activity for 20 to 40 minutes, 3 to 5 days per week, if no medical contraindications exist.31

Diet. There is a paucity of good data regarding the potential protective effects of diet in secondary stroke prevention. Diets high in fruits and vegetables may have a protective effect against ischemic stroke.32

Current recommendations from the American Heart Association include 5 or more servings of fruits and vegetables per day, and 6 servings of grain products.31 They recommend limiting foods with high content of cholesterol raising fatty acids and food high in cholesterol.

| TABLE 2 |
| Factors determining management of symptomatic carotid stenosis |

<table>
<thead>
<tr>
<th>FAVORING MEDICAL THERAPY ALONE</th>
<th>FAVORING CEA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stenosis &lt;50%</td>
<td>Stenosis 70%–99%*</td>
</tr>
<tr>
<td>Stenosis 50%–69%, with qualification†</td>
<td>Age ≥75 years</td>
</tr>
<tr>
<td>String sign†</td>
<td>Hemispheric stroke</td>
</tr>
<tr>
<td>Last symptoms &gt;3 years earlier</td>
<td>Last symptoms ≤2 weeks earlier</td>
</tr>
<tr>
<td>TMB only symptom</td>
<td>Contralateral occlusion</td>
</tr>
</tbody>
</table>

* Consider angioplasty with or without stenting in patients with symptomatic stenosis 70% to 99% who have failed medical management and are not candidates for CEA.
† Arrange for serial imaging every 6 to 12 months, and consider CEA if stenosis increases to >70%
‡ String sign is an angiographic finding of severe carotid stenosis associated with distal collapse of the internal carotid artery in the neck.

CEA, carotid endarterectomy; TMB, transient monocular blindness.

**Step 2: Clear blocked arteries**

**Carotid stenosis**

Carotid stenosis was recognized as an important risk factor for stroke in the 1950s. Carotid endarterectomy (CEA) was reported as a putative therapy shortly thereafter. The popularity of the surgery increased steadily through the mid-1980s despite an absence of evidence for the operation’s safety or efficacy. Trials were organized in North America and Europe to test the surgery’s potential risks and benefits. More recently, trials comparing CEA to angioplasty with and without stenting were organized.

**Clinical trials with carotid endarterectomy/angioplasty, with or without stenting.** Several multicenter trials have explored the benefit of CEA for symptomatic patients with varying degrees of ipsilateral carotid artery stenosis. These trials found a high degree of benefit for best medical management plus CEA compared with medical treatment alone for symptomatic patients with high-grade stenosis (70% to 99%), but only moderate stroke risk reduction with moderate carotid stenosis (50% to 69%). With mild stenosis (<50%), no benefit was found for surgical intervention.34

Even for patients with 70% to 99%
stenosis, benefit can be eliminated by a high rate of perisurgical complications. Surprisingly, CEA was also of little or no benefit for patients with symptomatic carotid near occlusion.

Other factors influencing the relative benefit of CEA include gender (men benefit more than women), age ≥75 years (older patients do better), and timing of surgery (maximum benefit when done within 2 weeks of the most recent symptoms).

Devices for performing carotid angioplasty with or without stenting were recently approved by the Food and Drug Administration. However, this is a new technology that has not been proven superior to CEA for most patients with symptomatic stenosis.

Applying the evidence. Be sure all patients with severe or moderate stenosis receive appropriate surgical evaluation for CEA (Table 2). For symptomatic patients with very high-grade carotid stenosis and surgical risks so high that the surgeon believes CEA is not an option, carotid angioplasty and stenting can be considered. A recent trial found a trend toward non-inferiority for angioplasty and stenting compared with CEA in a high-risk population. However, widespread application of this technique should await completion of clinical trials testing it in more typical cerebrovascular patients.

Intracranial stenosis
Patients found to have ischemic stroke secondary to intracranial large artery stenosis or occlusion present a difficult therapeutic problem. An attempt to bypass the blocked artery was studied in a large prospective randomized trial of extracranial to intracranial bypass surgery. While the study remains controversial to this day, it failed to show any benefit for surgery compared with best medical management. A study is now underway to examine whether patients selected for the procedure based on results of positron emission tomography will benefit.

Attempts to open stenotic and even occluded intracranial arteries have been reported in anecdotal series. However, the safety, efficacy, and durability of these procedures in this setting are speculative and should only be considered in exceptional circumstances.

Medical management of intracranial stenosis is also controversial. A retrospective study suggested that these patients may do better with anticoagulation compared with aspirin. However, a prospective randomized trial found that warfarin was no more effective than aspirin and increased risk.

Applying the evidence. At this time, patients who have ischemic stroke due to large artery intracranial stenosis should be treated with best medical management including risk reduction and antithrombotic agents (see below). Bypass or angioplasty should be considered only if medical management fails.

Step 3: Thin the blood
Anticoagulation
Warfarin is appropriate for primary stroke prevention in many patients with AF and for secondary prevention in most AF patients with a history of embolic events. For secondary prevention, warfarin is 68% better than placebo and significantly better than aspirin. Appropriate timing of warfarin therapy following ischemic stroke or TIA is controversial. Some trials indicate that the risk without acute anticoagulation is fairly low in the first 2 weeks following an initial stroke, and that the risk of recurrent stroke does not diminish with anticoagulation.

Anticoagulation for secondary stroke prevention in patients with noncardioembolic stroke is an unsettled issue.
in the anticoagulation arm led to early termination of this study. The hazard ratio associated with the use of anticoagulants was 2.3 (95% confidence interval [CI], 1.6–3.5). Intracranial hemorrhage was the most frequently encountered bleeding complication.

The Warfarin-Aspirin Recurrent Stroke Study (WARSS) was conducted with 2206 patients who had suffered recent noncardioembolic ischemic strokes. Dose-adjusted warfarin (INR=1.4–2.8) was compared with aspirin 325 mg daily. The primary end point of death or recurrent ischemic stroke occurred in 16.9% of patients. No significant differences in efficacy were found between warfarin and aspirin. Safety profiles were similar as well, although patients taking warfarin had significantly more minor hemorrhages than did those in the aspirin group. The Warfarin-Aspirin in Symptomatic Intracranial Disease trial compared dose-adjusted warfarin (INR=2–3) with aspirin 1300 mg/d in 569 patients with symptomatic intracranial stenosis. They recently reported a recurrent stroke rate of 11% to 12% for each treatment arm, with a somewhat higher rate of hemorrhage in the patients receiving warfarin.

Applying the evidence. Given the absence of data favoring warfarin for secondary stroke prevention in most ischemic stroke settings apart from cardioembolic stroke, using antiplatelet agents as a first line therapy is reasonable. Based on subset analysis of data from the WARSS trial, prescribing warfarin for patients who have failed aspirin is not a reasonable choice for most patients.

Antiplatelet agents

Aspirin. Aspirin both inhibits and promotes thrombogenesis. In its antithrombotic activity, aspirin inactivates platelet cyclooxygenase irreversibly—which, in turn, inhibits formation of thromboxane A2, a potent stimulator of platelet activation and vasoconstriction. This irreversible inhibition lasts for the lifespan of the platelet (about 7 to 10 days). Aspirin’s prothrombotic action comes from blocking production of endothelial prostacyclin, a prostaglandin that causes vasodilation and disaggregation.

Aspirin is the most commonly prescribed drug for prevention of secondary stroke. Yet, despite 21 randomized clinical trials involving more than 18,000 participants, consensus is lacking on many aspects of using aspirin for stroke prevention. In a meta-analysis of trials enrolling patients with previous TIA or stroke, treatment with antiplatelet agents compared with control reduced the rate of subsequent nonfatal stroke from 10.8% to 8.3%.

Aspirin has significant gastrointestinal (GI) toxicity and causes GI bleeding. The relative risk of developing peptic ulcer is 1.3, and symptoms of upper gastrotoxicity may cause withdrawal from aspirin treatment. Hemorrhagic stroke increases with aspirin use, but for patients at risk for secondary ischemic stroke, aspirin’s antithrombotic benefit outweighs the increased risk of hemorrhagic stroke (or GI toxicity).

Aspirin dosing is controversial despite a large number of randomized, controlled trials. Faced with the same published papers and involvement in many of the same studies worldwide, experts fail to reach consensus on an optimal dose between 30 mg and 1500 mg. When aspirin is the antiplatelet drug of choice, absent data to show that higher dosing provides greater benefit, it is reasonable to use daily doses between 50 mg and 325 mg.

Ticlopidine. Ticlopidine is a thienopyridine derivative that irreversibly inhibits platelet aggregation by blocking the adenosine diphosphate (ADP) receptor, and it requires metabolism in the liver for this activity to take place. Ticlopidine, given 250 mg twice a day, inhibits platelet function within 24 to 48 hours of administration, peaks at 3 to 7 days, and lasts for the lifespan of the platelet. Bleeding time is doubled and remains prolonged for 4 to 10 days after the last dose.

The Ticlopidine Aspirin Stroke Study (TASS) examined the effects of ticlopidine 500 mg versus aspirin 1300 mg on the risk
of stroke or death in 3069 patients with recent ischemic events. Ticlopidine was more effective than aspirin in reducing the risk of death from any cause or nonfatal stroke.\(^46\) The risk of fatal or nonfatal stroke was reduced by 21% compared with aspirin.\(^46\)

Subgroup analysis of TASS suggested a more favorable benefit-to-risk ratio for nonwhite patients compared with white patients.\(^47\) In an attempt to validate this subgroup analysis, a second study, the African American Antiplatelet Stroke Prevention Study (AAASPS), randomized 1809 black patients with recent noncardioembolic stroke to receive ticlopidine 500 mg/d or aspirin 650 mg/d, and followed them for 2 years. The researchers reported no difference between the agents in the prevention of recurrent stroke, MI, or vascular death.\(^48\)

Unfortunately, the clinical usefulness of this compound is limited by side effects. Diarrhea and skin rash, the most common side effects, were usually relieved by a temporary reduction in dose. However, severe reversible neutropenia occurred in nearly 1% of patients.\(^46\) Potentially life-threatening thrombotic thrombocytopenic purpura has also been associated with ticlopidine. The potential for a serious adverse event requires that patients be carefully monitored during the first 3 months of treatment.\(^46\) This side effect profile makes ticlopidine a poor choice as a first-line drug for secondary stroke prevention.

**Clopidogrel.** Like ticlopidine, clopidogrel is a thienopyridine derivative and blocks the ADP receptor. Clopidogrel's antiplatelet effect is dose-related, with 75 mg causing prolongation of bleeding time roughly equivalent to 500 mg of ticlopidine. After a loading dose of 300 mg, the onset of action is about 2 to 5 hours, and peak platelet inhibition occurs between 3 and 7 days. Like ticlopidine, bleeding time remains prolonged for 4 to 10 days after the last dose.

The **Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events** (CAPRIE) trial evaluated clopidogrel (75 mg once daily) in reducing the risk of the combined outcome of ischemic stroke, MI, or vascular death in more than 19,000 patients who entered the trial with recent ischemic stroke, recent MI, or symptomatic peripheral vascular disease.\(^49\) A modest but statistically significant relative risk reduction of 8.7% was found for clopidogrel over aspirin (95% CI, 0.3–16.5; \(P=0.043\)). For the subgroup of patients entering the trial with stroke, there was a risk reduction of 7.3% favoring clopidogrel, but this did not reach statistical significance (95% CI, –5.7 to 18.7; \(P=0.26\)).

The main adverse events experienced by patients taking clopidogrel were diarrhea and rash. Patients taking aspirin experienced gastrointestinal discomfort and, more seriously, a small but statistically significant increase in gastrointestinal hemorrhage.\(^49\)

The **Clopidogrel in Unstable Angina to Prevent Recurrent Events** (CURE) trial examined the effects of clopidogrel plus aspirin compared with aspirin alone on the combined end point of: (1) cardiovascular death, MI, or stroke; and (2) cardiovascular death, MI, stroke, or refractory ischemia in 12,562 patients with an acute coronary syndrome without ST segment elevation. Combination antiplatelet therapy demonstrated a relative risk reduction of 20% (95% CI, 0.72–0.90; \(P<0.001\); absolute risk reduction [ARR]=2.1%) and 16% (95% CI, 0.79–0.94; \(P<0.001\); ARR=2.3%) for the 2 primary endpoints compared with aspirin alone. Major bleeding was significantly more common in the clopidogrel plus aspirin group (relative risk increase of 38%; 95% CI, 1.13–1.67; \(P=0.001\); absolute risk increase =1%).

The applicability of the CURE trial findings to a stroke population is questionable, however. This trial addressed neither the efficacy nor the safety of this combination in a stroke population. Results were recently reported by the **Management of Atherothrombosis with Clopidogrel in High Risk Patients with Recent Transient Ischemic Attack or Ischemic Stroke** (MATCH) trial, which compared clopidogrel alone with clopidogrel plus aspirin in...
a population of patients with recent stroke or TIA plus 1 vascular risk factor.51

Researchers reported no significant difference in prevention of a combined vascular outcome or in preventing ischemic stroke alone. They did find a significant increase in life-threatening bleeding and major bleeding using the combination of aspirin and clopidogrel. Unfortunately, this trial did not address the issue of safety or efficacy of the combination of aspirin plus clopidogrel versus aspirin alone. The Stroke Prevention in Small Subcortical Strokes (SPS3) trial, an NINDS-funded study, will address this question, but the results of that trial are several years away.

Lau and colleagues52 report that the platelet inhibition activity of clopidogrel was attenuated in patients undergoing coronary artery stent implantation and who were being treated with 10 to 40 mg of atorvastatin. Antiplatelet activity was significantly attenuated for up to 8 days after stent implantation in these patients, compared with clopidogrel alone.

Based on the data, clopidogrel is the first-line drug of choice for secondary stroke prevention for patients unable to take aspirin. The combination of aspirin plus clopidogrel has increased risk without increasing efficacy and, therefore, is not a reasonable first-line choice for secondary stroke prevention.

Aspirin plus extended-release dipyridamole (ER-DP). Dipyridamole reversibly inhibits platelet activity by inhibiting both platelet phosphodiesterase and the uptake of adenosine. For the standard release formulation, the time to peak concentration varies from 34 to 75 minutes.53 Standard-release dipyridamole falls below its therapeutic level about 6 to 8 hours after the last dose. And because its inhibition of platelet function is reversible, 3 to 4 daily doses of the drug are necessary to maintain the desired antiplatelet effect.54 ER-DP reportedly requires twice daily dosing and achieves a therapeutic steady state after approximately 48 hours. Combining aspirin with ER-DP has the potential for taking advantage of the inhibition of the platelet cyclooxygenase and phosphodiesterase plus the platelet uptake of adenosine.

The second European Stroke Prevention Study (ESPS-2) investigated, in a population at high risk for stroke, the safety and efficacy of 4 antiplatelet strategies: (1) aspirin 25 mg twice daily; (2) extended-release dipyridamole 200 mg twice daily; (3) combination aspirin 25 mg plus extended-release dipyridamole 200 mg twice daily; (4) and placebo.55

Compared with placebo, aspirin alone reduced stroke risk by 18.1% (P=.013), dipyridamole alone by 16.3% (P=.039), and the combination agent by 37.0% (P<.001). The relative risk reductions for the combined end point of stroke or death were 13.2% (P=.016) with aspirin, 15.4% (P=.015) with dipyridamole, and 24.4% (P<.001) with the combination agent.

Headache and gastrointestinal disturbances were common adverse events in all treatment groups, but bleeding episodes were more frequent and severe only in the regimens that contained aspirin.55 In the aspirin group, 8.2% of patients reported bleeding, while in the aspirin plus ER-DP group, 8.7% reported bleeding.

This was the first trial to demonstrate that very-low-dose aspirin is effective in preventing secondary stroke.55 Efficacy was also found for extended-release dipyridamole as a single agent. The risk reduction achieved with the combination agent was approximately double that of either component alone.55 Aspirin plus ER-DP reduced stroke risk by 23% over aspirin alone.56

In progress now are trials validating ESPS2, comparing clopidogrel plus aspirin with aspirin alone, and comparing combination aspirin plus ER-DP with clopidogrel.

Applying the evidence. Until these trials are complete, reasonable first-line choices for secondary stroke prevention are aspirin alone or in combination with extended-release dipyridamole.

Reasonable first-line choices for secondary stroke prevention are aspirin alone or in combination with extended-release dipyridamole.

DISCLOSURE
Dr Cohen has received grant/research support and has served on speakers’ bureaus for Boehringer-Ingelheim Pharmaceuticals.

420
VOL 54, NO 5 / MAY 2005 THE JOURNAL OF FAMILY PRACTICE
REFERENCES


Look for the
CME/CE/CEU Supplement

New Options in Hormone Therapy:

Safety, Efficacy, and
What Your Patients Need to Know

TOPICS

- Cardiovascular Disease and Hormone Therapy:
  What the data show
  David F. Archer, MD
  Professor of Obstetrics and Gynecology
  Eastern Virginia Medical School

- Assessing Risks and Benefits of Hormone Therapy for the Individual Patient:
  Breast cancer, osteoporosis, and cognitive decline
  James A. Simon, MD
  Clinical Professor of Obstetrics and Gynecology
  George Washington University School of Medicine

- New Hormone-Therapy Formulations and Routes of Delivery:
  Meeting the needs of your patients in the post-WHI world
  Vivian Lewis, MD
  Strong Fertility and Reproductive Science Center
  University of Rochester Medical Center

Look for this supplement at www.obgmanagement.com.

The American Society for Reproductive Medicine is accredited by the ACCME to provide continuing medical education for physicians and by the National Association of Nurse Practitioners in Women’s Health to provide CE for nurse practitioners.

Medical Education Resources, a nonprofit medical education company, is accredited by the Accreditation Council for Pharmacy Education as a provider of CEU. Supported by an unrestricted educational grant from Solvay Pharmaceuticals, Inc.

This supplement is based on symposium presentations from ASRM’s 2003 Annual Meeting in San Antonio, Texas.

APPLIED EVIDENCE


